Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/24/22
Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care ConferenceGlobeNewsWire • 03/01/22
Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/14/22
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus NephritisGlobeNewsWire • 01/18/22
Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant PatientsGlobeNewsWire • 12/17/21
Vera Therapeutics Announces Appointment of Kimball Hall to Board of DirectorsGlobeNewsWire • 12/14/21
Vera Therapeutics to Present at Upcoming Investment Conferences in November 2021GlobeNewsWire • 11/10/21
Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/21
Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021GlobeNewsWire • 11/04/21
Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual MeetingGlobeNewsWire • 10/13/21
Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/16/21
Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 06/24/21
Vera Therapeutics to Participate in the Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/27/21